about
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytesDelayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient miceBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementAdaptive immune response in JAM-C-deficient mice: normal initiation but reduced IgG memoryIL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cellsInternational and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationRituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype.Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins.Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsCytokine inhibitors in the treatment of rheumatoid arthritis.Systemic rheumatoid vasculitis: a review.IL-1 trap. Regeneron/Novartis.Interleukin-6 and chronic inflammationThe role of leptin in innate and adaptive immune responsesLimited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection.Cytokines in the rheumatic diseases.Specific role of interleukin-1 in hepatic neutrophil recruitment after ischemia/reperfusion.Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal studyMolecular characterization and subcellular localization of macrophage infectivity potentiator, a Chlamydia trachomatis lipoprotein.EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.Expression and function of junctional adhesion molecule-C in human and experimental arthritis.Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonistsIs IL-1 a good therapeutic target in the treatment of arthritis?Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency.The severity of experimental arthritis is independent of IL-36 receptor signaling.Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease.Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.At the horizon of innovative therapy in rheumatology: new biologic agents.A systematic review of infliximab in the treatment of early rheumatoid arthritis.IL-1, IL-18, and IL-33 families of cytokines.Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice.Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
P50
Q24800491-A7EED26B-7C83-4BBB-ACEF-A43B914C625FQ24800930-3673317C-FF68-4214-8361-AB11EB0CE5C6Q27021115-45517576-5C6A-43F5-9931-F4C183C0C99CQ28513545-00098595-DE32-4808-AF67-0E31E70A2A3AQ28594649-5417CF72-C185-4DBE-AFAC-500472A7ABD5Q30234696-8EA514C7-5B8B-4D88-B3BD-A1CBF70235ECQ30400508-DBC01CBE-F6DA-466B-9F27-C5237413C7FEQ30940329-1006ECC4-B1B3-4D47-96C1-BDD1279BBFA6Q31046441-F134451D-DF15-4596-AEB2-2688426AEC9AQ31154802-4E3C5DE1-6D88-4A86-91C1-CB76F22A3D6AQ33553954-C59CA781-3D4A-44FD-959A-47037516A7E0Q33693897-A2AE61CE-749F-4897-8719-CA64B41242BCQ33899815-A4363D5A-9179-4E7C-9985-6BDCA4174102Q33923250-49893CAE-13D2-4811-8111-B0F642E622CBQ34110066-AD459904-4B17-4D7B-ACAE-F807B953DC25Q34534268-81EE5084-83A8-4424-AB86-133439D3053DQ34571785-F2EFE9E5-6E97-440A-A959-2BE5284B0E3FQ35165990-194745FB-346C-44AF-A53E-462F25DB7CDCQ35578869-B9B0F6B5-573B-4884-A60B-D6BD264BB796Q35605670-E998A5C7-CCEF-4577-B2AF-AED0B0704B1AQ35623978-B0CFA57A-FD82-4FCF-B804-6055BA4429C9Q35733792-01C53043-1A19-4876-BB99-BBB81F620123Q35747815-C25EA904-7EB6-4694-845C-842D4CF221A3Q35782767-97801927-EA1A-4109-997F-FD879BB34221Q35879416-5B9FD04D-97D7-4D10-8D67-8676AB458B6BQ35896648-300846C6-7CCF-4330-8218-E51B241A58D7Q36392352-343A36F5-2A44-4425-B219-59E093FFBB98Q36406242-529433BE-DCDF-4B9E-BD7D-AA594ECA0FFEQ36596137-400D7840-5288-49ED-84EC-C416DC66AA62Q36677277-1231C1E1-DF34-456B-AD51-458AB0D49417Q36823811-B1C2F420-4C2E-4423-8E2B-730E9458AFBCQ36903150-11983F8F-43E1-46E2-89E5-6C30D87421E8Q36903300-57E21B6D-D9EC-4EAA-8852-48BF35A7D7DBQ36907619-DA9787E7-4215-4EC5-AC9B-4482C96D44A6Q37085666-9AD5129F-EBCF-476B-89B4-64E1F39AD542Q37128310-FB90AB7C-D420-4D65-B2A6-8F5FFC0451BCQ37160391-AE85EED7-492F-4DE8-85B3-E28C68F4E025Q37211243-3A192BC2-1588-441B-99AA-0769C5290480Q37270779-A58E6C7C-1DB0-4D5D-9EE4-D6BE8C682F4FQ37282484-C7E1955C-86FA-4A20-B2B3-428F9FE07B17
P50
name
Cem Gabay
@ast
Cem Gabay
@en
Cem Gabay
@nl
type
label
Cem Gabay
@ast
Cem Gabay
@en
Cem Gabay
@nl
prefLabel
Cem Gabay
@ast
Cem Gabay
@en
Cem Gabay
@nl
P214
235155042730072400676
P31
P7859
viaf-235155042730072400676